Gary S. Hogge - 11 Feb 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
SVP,Clinical & Medical Affairs
Signature
/s/ Grant Harbert, as Attorney-in Fact
Issuer symbol
LCTX
Transactions as of
11 Feb 2022
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 18:42:43 UTC
Previous filing
30 Dec 2021
Next filing
11 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Award $0 +52,081 $0.000000 52,081 11 Feb 2022 Common Shares 52,081 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.
F2 Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023.